Prospective Open-Labeled Non Randomised Phase-II Study of SU011248 (Sunitinib) in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer - A CUOG [Canadian Urologic Oncology Group]/ GTCSG [German Testicular Cancer Study Group] Cooperative Phase II Study.
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Sunitinib (Primary)
- Indications Germ cell and embryonal neoplasms
- Focus Therapeutic Use
- 14 Jul 2009 Actual initiation date (Nov 2006) and actual patient number (33) added as reported by ClinicalTrials.gov.
- 14 Jul 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
- 14 Jul 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.